Genomics is the battleground for some of the cloud, Big Data and analytics vendors. As they view it as a proof for their ability to manage highly complex data. IBM has been talking about the ability of its analytics product, Watson, to help researchers identify new paths of investigation.
Maverix Biomics released latest analysis kits which enable researchers to look for variants in the whole genome, exome and target resequencing data produced by high throughput next generation sequencing systems. The solutions comply with Healthcare Insurance Portability and Accountability Act (HIPAA). They also form part of yhe Maverix Analytics Platform.
This appears far from corporate big data and analytics but it is not. Maverix Analytics Platform is a PaaS (Platform as a service) offering that can be used to manage, explore and visualise genomic data. It enables researchers to mix publicly available data with their private data to carry out wider analytics and it does so while providing secure control of data.
This is a target market for IBM, for its Watson Analytics product and next year intends to provide a cloud service inside its Soft Layer cloud data centres to support medical charities, but Maverix is already providing the cloud based PaaS and it is the proof that complex analytics can be done in the cloud.
One of the areas that this kind of collaborative work is important is in cancer research. Scientists are looking at the genomics of cancer across multiple patients in order to map how it varies from patient to patient and even across multiple regions. This allows them to identify core genetic markers which can then be compared with healthy cells to discover what can be targeted by new medicines without affecting healthy cells.
This kind of collaborative work is crucial for Cancer Research. In this area, Scientists are looking at genetic data of cancer across a wide spectrum of patients in order to map the variations from patient to patient and across regions. This allows them to identify core genetic markers which can then be compared with healthy cells to discover what can be targeted by new medicines without affecting healthy cells.
Huge amounts of processing is required to deal with such large amounts of data and use variant modeling. This and the fact that it is important to share the data without compromising either the patients or research programmes is part of the Maverix Analytics platform.
The new Analytics Kits draw on peer-reviewed open-source tools that help to lower the cost of doing research. There are three mentioned by Maverix Biomics as part of this announcement:
FastQC - This provides a quality control check that ensures the raw data created by the sequencers is accurate and does not contain any bias that would impact results.<\li>
BWA - The Burrows-Wheeler Aligner maps low-divergent sequences against a large reference genome.
SnpEff - Designed to predict the impact of genetic variants which helps identify potential areas for future research.
While the focus of Maverix is on Genomics, there are parallels here in the commercial world where understanding the difference between actual and projected (product lines, sales etc.,) is crucial to business success. Vendors like Maverix have shown the proof that a fully functional cloud based analytics is possible, and with IBM’s Watson Analytics entering the market soon, we’d say it’s just the beginning of a new cloud based analytics era.
Global Association of Risk Professionals, Inc. (GARP®) does not endorse, promote, review or warrant the accuracy of the products or services offered by EduPristine for FRM® related information, nor does it endorse any pass rates claimed by the provider. Further, GARP® is not responsible for any fees or costs paid by the user to EduPristine nor is GARP® responsible for any fees or costs of any person or entity providing any services to EduPristine Study Program. FRM®, GARP® and Global Association of Risk Professionals®, are trademarks owned by the Global Association of Risk Professionals, Inc
CFA Institute does not endorse, promote, or warrant the accuracy or quality of the products or services offered by EduPristine. CFA Institute, CFA®, Claritas® and Chartered Financial Analyst® are trademarks owned by CFA Institute.
Utmost care has been taken to ensure that there is no copyright violation or infringement in any of our content. Still, in case you feel that there is any copyright violation of any kind please send a mail to firstname.lastname@example.org and we will rectify it.
2015 © Edupristine. ALL Rights Reserved.